ReviewDrug design, development and therapy2025
Copper-Induced Cell Death in Renal Diseases: Molecular Mechanisms and Therapeutic Implications.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metabolic pathways and cell death modalities in diabetic complications: unraveling pyroptosis, ferroptosis, cuproptosis, and disulfidptosis.Cell death discovery · 2026Review
- Mitochondrial dysfunction and the regulatory cell death crosstalk network in chronic obstructive pulmonary disease: from oxidative stress mechanisms to targeted therapeutic strategies.Frontiers in immunology · 2026Review
- Cuproptosis in Sepsis: Cell Type-Specific Mechanisms and Clinical Prospects.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Copper dyshomeostasis and the resulting induction of cuproptosis, a novel regulated cell death pathway driven by mitochondrial copper overload, play a critical role in renal pathophysiology. Cuproptosis is characterized by FDX1-mediated copper reduction, irreversible aggregation of lipoylated TCA cycle enzymes, such as dihydrolipoamide S-acetyltransferase, and destabilization of iron‒sulfur cluster proteins, leading to proteotoxic mitochondrial collapse. The kidney's high vulnerability arises from its filtration and metabolic functions. This review consolidates evidence linking cuproptosis to various renal disorders, including acute kidney injury (eg, sepsis-induced, cisplatin-induced, and ischemia-reperfusion injury), diabetic nephropathy through mitochondrial dysfunction and immune dysregulation, and chronic kidney disease involving podocyte damage or context-dependent dysregulation in fibrosis and clear cell renal cell carcinoma. Notably, cuproptosis and ferroptosis interact synergistically through shared mechanisms, where glutathione depletion or iron overload exacerbates both pathways, while mitochondrial dysfunction and lipid peroxidation create a self-perpetuating injury cycle. Emerging diagnostic strategies utilize cuproptosis-related biomarkers for early detection, supported by various prediction models. In therapeutic contexts, copper chelators, transporter modulators, and dual-pathway inhibitors targeting both cuproptosis and ferroptosis mitigate renal damage in preclinical models. Dietary interventions that modulate copper bioavailability also hold promise. However, challenges remain, including identifying renal cell type-specific mechanisms, developing noninvasive biomarkers, optimizing kidney-targeted nanotherapeutics, and preventing iatrogenic copper deficiency. Future research may focus on translational applications and the physiological roles of cuproptosis in renal repair. Targeting cuproptosis offers a promising avenue for innovative diagnostics and treatments in nephrology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.